Skip to content

Post Marketing Trial for Evaluating the Effectiveness of ActiGraft in Treating Lower Extremity Hard To Heal Wounds

A Prospective, Single Arm, Post Marketing Study for Evaluating the Effectiveness of ActiGraft in Treating Lower Extremity Hard to Heal Wounds

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04745806
Enrollment
6
Registered
2021-02-09
Start date
2021-03-01
Completion date
2023-01-01
Last updated
2024-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wounds

Keywords

Chronic, Ulcer, Lower extremity, DFU, VLU

Brief summary

The study is a prospective, single arm, post- marketing study. The subjects enrolled to the study will receive weekly applications of ActiGraft until complete healing or until investigator's decision that patient can no longer benefit from the study treatment.

Interventions

DEVICEActiGraft

Whole blood clot (WBC) gel

Sponsors

RedDress Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Subject is ≥18 years of age 2. Patient with a chronic lower extremity ulcer (i.e DFU, VLU, …) 3. Ulcer duration \>30 days. 4. Ulcer size decreased in less than 30% in the 14 days prior to enrollment, while treated with standard of care (or advanced treatment) 5. Subject must be willing to comply with the protocol including having blood drawn to create the ActiGraft 6. Subject can read and understand the Informed Consent form

Exclusion criteria

1. Presence of active underlying osteomyelitis. 2. Known malignancy in the reference wound bed or margins of the wound 3. Cannot withdraw blood in the required amount technically. 4. Subject is receiving (i.e., within the past 30 days) systemic steroids (more than 10mg per day) 5. Subject has been treated with wound dressings that include growth factors, engineered tissues or skin substitutes (within the past 30 days). 6. Subject has been treated with hyperbaric oxygen, wound VAC or Ozone gas(O3) within the past 5 days or is scheduled to receive during the study

Design outcomes

Primary

MeasureTime frameDescription
Percent of Reduction in Wound Size Over 12 Weeks4, 8, and 12 weeksThe change in wound area (decrease or increase) with respect to the area at baseline, expressed as a percentage.

Secondary

MeasureTime frameDescription
Number of Participants Achieving a Complete Wound Closure at 12 Weeks12 weeksSkin re-epithelialization without drainage or dressing requirements.
Number of Participants Achieving a Complete re-epithelialization at 18 and 24 Weeks18 and 24 weeksSkin re-epithelialization without drainage or dressing requirements.
Percent of Reduction in Wound Size Over 18 and 24 Weeks.18 and 24 weeksThe change in wound area (decrease or increase) with respect to the area at baseline, expressed as a percentage for wound treated beyond 12 weeks, per the investigator's decision
The change in wound pain by 12 weeks12 weeksPain assessment would be done by using the Numeric Rating Scale (NRS). Subject chooses a number on a 1 to 10 scale that best describes his ulcer pain, while 0 represents No Pain and 10- Worst Pain Imaginable test, a scale between .

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026